clinical trials
-
Still Here, January 17: Links and transcript
Freelance reporter and Long COVID patient advocate Sam Rhodehamel discusses the COVID-19 mutual aid groups helping protect L.A.-area residents during wildfires. Also, an update on NIH RECOVER-TLC and the latest COVID-19 numbers.
-
Research updates, January 14
-
Still Here, January 10: Links and transcript
Investigative journalist and author Violet Blue discusses the COVID Safety Handbook. Also, the latest COVID-19 numbers, and looking at longer Paxlovid courses.
-
Research updates, January 7
*Editor’s note: Julia Moore Vogel, an author of Paxlovid study, is on The Sick Times’ advisory board. Other authors are also affiliated with the Patient-Led Research Collaborative, which shares a funding source (the Balvi and Kanro funds) with The Sick Times. One author (JD Davids) is affiliated with Long COVID Justice, with which we collaborated…
-
Still Here, December 20: Links and transcript
In the last episode of 2024, recapping freelancer Hannah Buttle’s reporting on how the treatment landscape for Long COVID has pushed some to look to online drug markets. Also in this episode: the latest COVID-19 numbers, and more research funding, plus some podcast stats.
-
Still Here, December 13: Links and transcript
This week, playwright and rock musician Dan Fishback talks about his new production about living with ME/CFS in a pandemic. Also in this episode: the latest COVID-19 numbers, a randomized, controlled clinical trial looking at the monoclonal antibody Evusheld 2.0, and Mt. Sinai’s Cohen Center for Recovery from Complex Chronic Illness (CoRE) looks for new…
-
NIH announces $147 million in additional Long COVID research funding, new budget details
The U.S. National Institutes of Health (NIH) has announced further funding for its flagship Long COVID research program, called RECOVER, as well as new details about the program’s budget through 2029. RECOVER will receive an additional $147 million, building on $515 million allocated earlier this year and the original $1.15 billion funded by Congress in…
-
With no approved treatments and little support, people with Long COVID turn to online drug markets
With no approved treatments, lack of support, and stigma against the disease, many people with Long COVID are using overseas pharmacies to source medications. Some of these treatments are widely used for other conditions, such as HIV and hepatitis C, but are not approved for use in Long COVID.
-
Research updates, December 10
-
Still Here, December 3: Links and transcript
This week, co-host Betsy Ladyzhets talks with producer James Salanga about what the potential Long COVID research landscape could look like under Trump.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance